SCHEMBL842227

SCHEMBL842227

Nc1nc2[nH]c(=S)[nH]c(=O)c2s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.70
MAPT P10636 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
PKM P14618 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
USP2 O75604 1/20 0.37
GLA P06280 1/20 0.37
THRB P10828 1/20 0.37
TNNI3 P19429 1/20 0.37
TNNT2 P45379 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
TNNC1 P63316 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
PTPN22 Q9Y2R2 1/20 0.37
CXCR2 P25025 3/20 0.36
CXCR1 P25024 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755970 0.82 RPS6KA3 (1.00) RPS6KA3MAPTMEN1KMT2AKDM4E
SCHEMBL6866810 0.68 RPS6KA3 (0.53) RPS6KA3CXCR2CXCR1
Thiazolopyrimidine SCHEMBL1703410 0.67 RPS6KA3 (0.52) RPS6KA3MAPTMEN1KMT2AKDM4E
SCHEMBL8435570 0.64 RPS6KA3 (0.49) RPS6KA3MAPTKDM4EGLATHRB
SCHEMBL5036641 0.64 RPS6KA3 (0.48) RPS6KA3MAPTKDM4EALDH1A1HPGD
SCHEMBL5479007 0.64 MAPT (0.62) MAPTMEN1KMT2AKDM4EPKM
SCHEMBL6425971 0.61 RPS6KA3 (0.45) RPS6KA3MAPTKDM4ETDP1CXCR2
SCHEMBL5039659 0.60 RPS6KA3 (0.44) RPS6KA3MAPTKDM4EPKMTDP1
SCHEMBL159446 0.60 MAPT (0.68) MAPTMEN1KMT2AKDM4EPKM
SCHEMBL11736849 0.60 KDM4E (0.46) MAPTMEN1KMT2AKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143261-B2 Thiazolo (4,5-D) pyrimidine compounds ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20090281123-A1 NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS ASTRAZENECA UK LIMITED 2009-11-12 US disclosed
EP-1348709-B1 Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis ASTRAZENECA UK LTD (GB) 2008-01-16 EP disclosed
US-20060111569-A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity BONNERT ROGER 2006-05-25 US disclosed
US-6949643-B2 Thiazolopytimidines and their use as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2005-09-27 US disclosed
EP-1385854-B1 THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2005-02-09 EP disclosed
US-20040224961-A1 Novel thiazolo (4,5-D) pyrimidine compounds ASTRAZENECA UK LIMITED, A BRITISH CORPORATION 2004-11-11 US disclosed
US-6806273-B1 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS ASTRAZENECA AB (SE) 2004-10-19 US disclosed
US-6790850-B1 Thiazolo(4,5-d)pyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2004-09-14 US disclosed
US-20040157853-A1 Thiazolopytimidines and their use as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-08-12 US disclosed
EP-1222195-B1 NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2004-01-14 EP disclosed
EP-1348709-A2 Thiazolo (4,5-D) pyrimidine compounds AstraZeneca UK Limited (GB) 2003-10-01 EP disclosed
EP-1104425-B1 NOVEL THIAZOLOPYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2003-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111569-A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity CXCR2, CCR5, CXCR1 RPS6KA3 3055/4885MAPT 3780/4885MEN1 4451/4885
US-20040157853-A1 Thiazolopytimidines and their use as modulators of chemokine receptor activity CCR5, CCR2, CX3CR1 RPS6KA3 3071/4885MAPT 1908/4885MEN1 4367/4885
US-20040224961-A1 Novel thiazolo (4,5-D) pyrimidine compounds TYMS, DPYD, TYMP RPS6KA3 2814/4885MAPT 857/4885MEN1 3011/4885
US-20090281123-A1 NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS TYMS, DPYD, TPMT RPS6KA3 2459/4885MAPT 1022/4885MEN1 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.